May 25, 2005 11:24 ET

FDA Advisory Panel Meeting for Nymox PMA Application Expected in July 2005

MAYWOOD, N.J.--(CCNMatthews - May 25, 2005) -

Nymox Pharmaceutical Corporation (NASDAQ:NYMX) announced today that it has been informed that the Company's Premarket Approval (PMA) application to FDA concerning a kit version of the Company's AlzheimAlert™ urine test will be going forward to a presentation before a panel of the Medical Devices Advisory Committee which is expected in July of this year. This step follows the submission to the FDA of further data and analyses by the Company. The exact date for the panel meeting will be confirmed in due course.

Advisory panels provide FDA with recognized expertise, independent judgment and recommendations about the safety and effectiveness of medical devices. FDA considers such recommendations but is not bound by them when making its final decision about whether to approve the Company's PMA.

In the PMA, the Company is seeking FDA approval to sell kit versions of its AlzheimAlert™ test to qualified laboratories and hospitals in the United States. AlzheimAlert™ is the Company's proprietary urine test intended to aid physicians in the diagnosis of Alzheimer's disease. The test measures levels of a brain protein called neural thread protein (NTP) known to be elevated in the brain tissue, cerebrospinal fluid and urine of patients with Alzheimer's disease.

AlzheimAlert™ is already certified as a laboratory testing service in the U.S. through the Company's CLIA-certified clinical reference laboratory in Maywood, New Jersey. A kit version of AlzheimAlert™ is also available for sale in Europe as a result of its certification with a CE Mark, making the test kit eligible for sale in the European Union.

There is an extensive scientific and medical literature on the usefulness of NTP as a biomarker for Alzheimer's disease. Publications include, for example, Journal of Alzheimer's Disease (2004; 6(3): 231-42) and (2001; 3: 345-353); Cellular and Molecular Life Sciences (2003; 60: 2679-91) and (2001; 58: 844-849); Alzheimer's Reports (2002; 1: 1-6); Neurology & Clinical Neurophysiology (2002; 1: 2-7); Frontiers in Bioscience (2002; 7:d989-96); Journal of Neuropathology and Experimental Neurology (2001; 60: 195-207) and (1996; 55: 1038-1050); Neurology (2000; 55: 1068) and (2000; 54: 1498-1504); Alzheimer's Reports (2001; 4: 61-65), (2000; 3: 177-184) and (1999; 2: 327-332); Journal of Clinical Laboratory Analysis (1998; 12: 285-288) and (1998; 12: 223-226); Journal of Contemporary Neurology (1998; 4A: 2-6); and Journal of Clinical Investigation (1997; 100: 3093-3104).

More information about Nymox is available at http://www.nymox.com, email: info@nymox.com, or 800-936-9669.

This press release contains certain "forward-looking statements" as defined in the United States Private Securities Litigation Reform Act of 1995 that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. The conduct of clinical trials and the development of drug products involve substantial risks and uncertainties and actual results may differ materially from expectations. Promising early results do not ensure that later stage or larger scale clinical trials will be successful or will proceed as expected. Such factors are detailed from time to time in Nymox's filings with the United States Securities and Exchange Commission and other regulatory authorities.

Contact Information